Equities research analysts expect Myovant Sciences Ltd (NYSE:MYOV) to announce ($0.93) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Myovant Sciences’ earnings. Myovant Sciences posted earnings of ($0.50) per share in the same quarter last year, which would suggest a negative year over year growth rate of 86%. The firm is scheduled to report its next quarterly earnings results on Monday, November 12th.

According to Zacks, analysts expect that Myovant Sciences will report full-year earnings of ($2.75) per share for the current financial year, with EPS estimates ranging from ($3.80) to ($1.70). For the next financial year, analysts forecast that the company will report earnings of ($3.38) per share. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Myovant Sciences.

Myovant Sciences (NYSE:MYOV) last issued its quarterly earnings data on Tuesday, August 7th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.08).

MYOV has been the topic of a number of recent analyst reports. Citigroup lifted their target price on Myovant Sciences from $17.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, April 25th. Zacks Investment Research raised Myovant Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, April 18th. Finally, ValuEngine raised Myovant Sciences from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $26.75.

Shares of Myovant Sciences traded down $0.63, reaching $21.31, during mid-day trading on Tuesday, according to MarketBeat.com. 53,902 shares of the company’s stock were exchanged, compared to its average volume of 170,364. Myovant Sciences has a 52 week low of $9.92 and a 52 week high of $25.54. The company has a current ratio of 3.07, a quick ratio of 3.09 and a debt-to-equity ratio of 0.73.

In other news, Director Mark Altmeyer bought 3,500 shares of the company’s stock in a transaction that occurred on Saturday, November 17th. The stock was bought at an average price of $13.38 per share, for a total transaction of $46,830.00. Following the transaction, the director now directly owns 3,500 shares of the company’s stock, valued at approximately $46,830. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.10% of the company’s stock.

A number of hedge funds have recently made changes to their positions in MYOV. Swiss National Bank increased its stake in shares of Myovant Sciences by 12.7% during the first quarter. Swiss National Bank now owns 28,300 shares of the company’s stock valued at $602,000 after buying an additional 3,200 shares during the period. JPMorgan Chase & Co. grew its stake in Myovant Sciences by 6.2% in the first quarter. JPMorgan Chase & Co. now owns 106,944 shares of the company’s stock worth $2,275,000 after purchasing an additional 6,263 shares during the period. Matisse Capital purchased a new stake in Myovant Sciences in the second quarter worth $349,000. Eventide Asset Management LLC grew its stake in Myovant Sciences by 3.9% in the first quarter. Eventide Asset Management LLC now owns 573,553 shares of the company’s stock worth $12,199,000 after purchasing an additional 21,453 shares during the period. Finally, Millennium Management LLC grew its stake in Myovant Sciences by 54.3% in the first quarter. Millennium Management LLC now owns 106,868 shares of the company’s stock worth $2,273,000 after purchasing an additional 37,602 shares during the period. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Recommended Story: What is the Book Value of a Share?

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.